U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H24O11.H2O
Molecular Weight 362.3276
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LACTITOL MONOHYDRATE

SMILES

O.OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO

InChI

InChIKey=LXMBXZRLTPSWCR-XBLONOLSSA-N
InChI=1S/C12H24O11.H2O/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12;/h4-21H,1-3H2;1H2/t4-,5+,6+,7+,8-,9-,10+,11+,12-;/m0./s1

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C12H24O11
Molecular Weight 344.3124
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Lactitol is a sugar alcohol. This ingredient has been determined to be GRAS for specified uses as a direct food additive and foods containing lactitol are eligible for a health claim related to dental caries. Lactitol is used as an oral powder or solution in the management of hepatic encephalopathy and in case of short-term treatment of occasional constipation. Intestinal flora of large intestine is metabolize lactitol to low-molecular organic acid, which leads to an increase in osmotic pressure in intestine, increase in volume of fecal masses bowel function normalization. This drug might cause abdominal discomfort, especially flatulence and abdominal pain rarely or sometimes abdominal distension. These effects tend to diminish or disappear after a few days of regular intake of the drug. Since 'antacids and neomycin can neutralize ' acidifying effect of lactitol on stool, they should not be co-administered with lactitol in cirrhotic patients with hepatic encephalopathy; however both substances do not alter the 'laxative effect in patients with constipation.

Originator

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Importal
Primary
Importal
PubMed

PubMed

TitleDatePubMed
Health potential of polyols as sugar replacers, with emphasis on low glycaemic properties.
2003 Dec
Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study.
2003 Mar
Effect of sugar alcohols on gut function and body composition in normal and cecectomized rats.
2004 Jul
Oxalate degradation by intestinal lactic acid bacteria in dogs and cats.
2004 Jul 14
Constipation in adults.
2004 Jun
Combination of polydextrose and lactitol affects microbial ecosystem and immune responses in rat gastrointestinal tract.
2004 Jun
Review: lactulose or lactitol may improve hepatic encephalopathy but may be less effective than antibiotics.
2004 Nov-Dec
Maximum permissive dosage of lactose and lactitol for transitory diarrhea, and utilizable capacity for lactose in Japanese female adults.
2005 Apr
[Nonabsorbable disaccharides for the treatment of hepatic encephalopathy--a systemic review of randomized clinical trials--a secondary publication].
2005 Jan 10
Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
2005 Jun 30
[Pneumatosis intestinalis in 9 children with an oncologic disease].
2005 Mar 19
Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.
2005 May
Short-chain fatty acid formation in the hindgut of rats fed oligosaccharides varying in monomeric composition, degree of polymerisation and solubility.
2005 Nov
Attenuated response of the serum triglyceride concentration to ingestion of a chocolate containing polydextrose and lactitol in place of sugar.
2005 Oct
[Intestinal function tests].
2005 Sep 14
Management of hepatic encephalopathy: focus on antibiotic therapy.
2006
[The diagnostics and therapy of hepatic encephalopathy. Recommendations of of the working group on portal hypertension in the Czech Hepatology Society and the J. E. Purkinje Czech Medical Society].
2006 Jan
Prevention of first overt episode of hepatic encephalopathy after TIPS: no easy task.
2006 May
Molecular mobility and dynamic site heterogeneity in amorphous lactose and lactitol from erythrosin B phosphorescence.
2006 Sep 20
Characterization of the bga1-encoded glycoside hydrolase family 35 beta-galactosidase of Hypocrea jecorina with galacto-beta-D-galactanase activity.
2007 Apr
Constipation in adults.
2007 Aug 1
Threshold for transitory diarrhea induced by ingestion of xylitol and lactitol in young male and female adults.
2007 Feb
Anemia impairs small intestinal absorption measured by intestinal permeability in children.
2007 Jan
Effects of lactitol on intestinal microflora and plasma endotoxin in patients with chronic viral hepatitis.
2007 Jan
A study of the properties of tablets from the mixtures of directly compressible starch and directly compressible lactitol.
2007 Jul
The trans-sialidase from Trypanosoma cruzi efficiently transfers alpha-(2-->3)-linked N-glycolylneuraminic acid to terminal beta-galactosyl units.
2007 Nov 26
[A case of recurrent pneumatosis cystoides intestinalis associated with recurrent pneumoperitoneum].
2007 Sep
Effects of low doses of lactitol on faecal microflora, pH, short chain fatty acids and gastrointestinal symptomology.
2007 Sep
Suppressive effect of partially hydrolyzed guar gum on transitory diarrhea induced by ingestion of maltitol and lactitol in healthy humans.
2007 Sep
Ecological characterization of the colonic microbiota of normal and diarrheic dogs.
2008
Prophylactic antibiotic treatment is superior to therapy on-demand in experimental necrotising pancreatitis.
2008
[Influence of the bifidobacteria and lactitol containing products on lypoperoxidation processes and intestinal microflora].
2008
Rifaximin for the treatment of hepatic encephalopathy.
2008 Aug
Accuracy of drug advertisements in medical journals under new law regulating the marketing of pharmaceutical products in Switzerland.
2008 Dec 31
Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study.
2008 Jan 15
Characteristic fragmentation patterns of the trimethylsilyl and trimethylsilyl-oxime derivatives of various saccharides as obtained by gas chromatography coupled to ion-trap mass spectrometry.
2008 Jan 4
Xylitol-supplemented nutrition enhances bacterial killing and prolongs survival of rats in experimental pneumococcal sepsis.
2008 Mar 11
Treatment of minimal hepatic encephalopathy.
2008 Nov
Sensory properties and color measurements of dietary chocolates with different compositions during storage for up to 360 days.
2009
The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.
2009
Influence of a combination of Lactobacillus acidophilus NCFM and lactitol on healthy elderly: intestinal and immune parameters.
2009 Feb
Standards of medical care in diabetes--2009.
2009 Jan
Some putative prebiotics increase the severity of Salmonella enterica serovar Typhimurium infection in mice.
2009 Nov 30
Idiopathic proximal hemimegacolon in an adult woman.
2010 Apr
Successful drug development despite adverse preclinical findings part 2: examples.
2010 Dec
Microbial and bioconversion production of D-xylitol and its detection and application.
2010 Dec 15
Constipation in adults.
2010 Jul 5
Xylo-oligosaccharides and lactitol promote the growth of Bifidobacterium lactis and Lactobacillus species in pure cultures.
2010 Jun
Synbiotic effects of lactitol and Lactobacillus acidophilus NCFM™ in a semi-continuous colon fermentation model.
2010 Jun
Recombinant human granulocyte colony stimulating factor pre-screening and screening of stabilizing carbohydrates and polyols.
2010 Mar 15
Patents

Sample Use Guides

In Vivo Use Guide
Initial dose - 20 g at once during 4-5 days. Next, 10 g per day.
Route of Administration: Oral
In Vitro Use Guide
The species of bifidobacteria, which were detected in vessel of each fermentation after adaptation to an Lactitol 1% (wt/vol): Bifidobacterium adolescentis, B. bifidum, B. longum, B. dentium and B. catenulatum. B. angulatum, B. breve and B. infantis were not detected.
Substance Class Chemical
Created
by admin
on Tue Oct 22 05:34:12 UTC 2019
Edited
by admin
on Tue Oct 22 05:34:12 UTC 2019
Record UNII
UH2K6W1Y64
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LACTITOL MONOHYDRATE
EP   II   MI   WHO-DD  
Common Name English
LACTITOL HYDRATE [JAN]
Common Name English
D-LACTITOL MONOHYDRATE
Common Name English
LACTITOL MONOHYDRATE [EP]
Common Name English
D-GLUCITOL, 4-O-.BETA.-D-GALACTOPYRANOSYL-, MONOHYDRATE
Common Name English
LACTITOL MONOHYDRATE [MI]
Common Name English
LACTITOL MONOHYDRATE [II]
Common Name English
LACTITOL MONOHYDRATE [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C283
Created by admin on Tue Oct 22 05:34:12 UTC 2019 , Edited by admin on Tue Oct 22 05:34:12 UTC 2019
Code System Code Type Description
EPA CompTox
81025-04-9
Created by admin on Tue Oct 22 05:34:12 UTC 2019 , Edited by admin on Tue Oct 22 05:34:12 UTC 2019
PRIMARY
RXCUI
1305520
Created by admin on Tue Oct 22 05:34:12 UTC 2019 , Edited by admin on Tue Oct 22 05:34:12 UTC 2019
PRIMARY RxNorm
PUBCHEM
3067270
Created by admin on Tue Oct 22 05:34:12 UTC 2019 , Edited by admin on Tue Oct 22 05:34:12 UTC 2019
PRIMARY
CAS
81025-04-9
Created by admin on Tue Oct 22 05:34:12 UTC 2019 , Edited by admin on Tue Oct 22 05:34:12 UTC 2019
PRIMARY
MERCK INDEX
M6659
Created by admin on Tue Oct 22 05:34:12 UTC 2019 , Edited by admin on Tue Oct 22 05:34:12 UTC 2019
PRIMARY Merck Index
NCI_THESAURUS
C77137
Created by admin on Tue Oct 22 05:34:12 UTC 2019 , Edited by admin on Tue Oct 22 05:34:12 UTC 2019
PRIMARY
EVMPD
SUB12097MIG
Created by admin on Tue Oct 22 05:34:12 UTC 2019 , Edited by admin on Tue Oct 22 05:34:12 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY